Despite the controversy surrounding the Aduhelm, a drug that, according to an advisory committee of independent experts and some specialists, is not backed up with enough evidence that actually serves as treatment against him Alzheimer. The US Food and Drug Administration, FDA, approved its use.
The endorsement of this drug accelerated, the FDA explained, because it is the first treatment that provided a “significant advance therapeutic“compared to other medicines, as it achieves an underlying reduction of beta plaques amyloid, which are a sign of the disease, providing an important benefit to patients Alzheimer’s.
“Although the Aduhelm data is complicated Regarding its clinical benefits, the FDA has determined that there is enough evidence that it reduces beta amyloid plaques in the brain, “the statement said.
According to the FDA, this medicine could generate adverse effects such as inflammations that disappear with time and do not initially cause symptoms, although they can cause headaches, dizziness or nausea, as well as hypersensitivity reactions such as hives
He was also asked Biogen, manufacturer of the treatment, who must submit a new, larger trial, with which to confirm the Benefits treatment, otherwise it could be withdrawn from the market.